John Lambert PhD GAICD
Chief Executive Officer
John has more than 16 years of drug discovery and development experience. His appointments include leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), as Senior Director (Medicines Development for Global Health) and as an academic researcher in medicinal and biological chemistry (University of Melbourne, ANU and Harvard University).
He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
John joined Amplia Therapeutics as Operations Manager in August 2018 and was appointed as CEO on 24 June 2019.
Mark Devlin B. Sc. (Hons) PhD GradD Drug Dev
Chief Scientific Advisor
After obtaining a PhD in Pharmacology from the University of Melbourne, Mark has worked in a variety of roles focused on preclinical drug discovery and development in a number of therapeutic areas including, pain, inflammation, autoimmune disease and oncology. Mark led the biology and later the project that delivered AMP945 and AMP886 and has a deep knowledge of the assets.
Mark is on the Scientific Advisory Committee to the Target and Drug Discovery Platform at the Australian National University, is an Associate Professor at the Peter MacCallum Cancer Centre, Chief Operating Officer for the CRC for Cancer Therapeutics (CTx) and is currently completing a MBA at the Melbourne Business School.
Chief Financial Officer
Mr Carter has been the Chief Financial Officer of Amplia Therapeutics Limited since 2013 and has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles. He has served as a member of the board on a USA based company. He was the chief financial officer of the company until it’s move to the USA at the end of 2009. Since the beginning of 2000 he has served as chief financial officer and company secretary of various publicly listed healthcare companies. Prior to his move into the healthcare sector he also held senior positions with Coca Cola, Santos, Canadian Imperial Bank of Commerce and Touche Ross.